J Biol Chem, Vol. 274, Issue 36, 25735-25742, September 3, 1999
cDNA Cloning and Chromosomal Localization of Human
11 Integrin
A COLLAGEN-BINDING, I DOMAIN-CONTAINING,
1-ASSOCIATED INTEGRIN
-CHAIN PRESENT IN MUSCLE
TISSUES*
Teet
Velling
,
Marion
Kusche-Gullberg§,
Thomas
Sejersen¶, and
Donald
Gullberg
From the
Department of Cell and Molecular Biology,
BMC, Box 596, Uppsala University, S-751 24 Uppsala, Sweden,
§ Department of Medical Biochemistry and Microbiology, BMC,
Box 575, Uppsala University, S-751 23 Uppsala, Sweden, and
¶ Department of Cell and Molecular Genetics, Karolinska
Institute, CMB, Doktorsringen 2D, 171 77 Stockholm, Sweden
 |
ABSTRACT |
We previously identified a novel integrin
-chain in human fetal muscle cells (Gullberg, D., Velling, T.,
Sjöberg, G., and Sejersen, T. (1995) Dev. Dyn. 204, 57-65). We have now isolated the full-length cDNA for this
integrin subunit,
11. The open reading frame of the
cDNA encodes a precursor of 1188 amino acids. The predicted mature
protein of 1166 amino acids contains seven conserved FG-GAP repeats, an
I domain with a metal ion-dependent adhesion site motif, a
short transmembrane region, and a unique cytoplasmic domain of 24 amino
acids containing the sequence GFFRS.
11, like other I
domain integrins, lacks a dibasic cleavage site for generation of a
heavy chain and a light chain, and it contains three potential divalent
cation binding sites in repeats 5-7. The presence of 22 inserted amino
acids in the extracellular stalk portion (amino acids 804-826)
distinguishes the
11 integrin sequence from other
integrin
-chains. Amino acid sequence comparisons reveal the highest
identity of 42% with the
10 integrin chain. Immunoprecipitation with antibodies to
11 integrin
captures a 145-kDa protein distinctly larger than the 140-kDa
2 integrin chain when analyzed by SDS-polyacrylamide gel
electrophoresis under nonreducing conditions. Fluorescence in
situ hybridization maps the integrin
11 gene to
chromosome 15q23, in the vicinity of an identified locus for
Bardet-Biedl syndrome. Based on Northern blotting, integrin
11 mRNA levels are high in the adult human uterus
and in the heart and intermediate in skeletal muscle and some other
tissues tested. During in vitro myogenic differentiation,
11 mRNA and protein are up-regulated. Studies of
ligand binding properties show that
11
1
binds collagen type I-Sepharose, and cultured muscle cells localize
11
1 into focal contacts on collagen type
I. Future studies will reveal the importance of
11
1 for muscle development and integrity
in adult muscle and other tissues.
 |
INTRODUCTION |
Integrins are heterodimers composed of noncovalently associated
- and
-chains that connect cells to the extracellular matrix or
to other cells (1). In addition to acting as mechanical links between
the cytoskeleton and extracellular ligands, integrins are
signal-transducing receptors that influence processes such as cell
proliferation, cell migration, and cell differentiation (2-4).
Integrins can be grouped into subfamilies based on shared
-chains,
shared ligand binding properties, or shared structural features of the
-chains. Currently, 17
-chains and 8
-chains have been
identified (5). Of the subfamilies with shared
-chains, the
1 subfamily has the most members. To date, 11 integrin
-chains associated with the
1 chain have been
identified and characterized,
1-
10 and
v (5).
Several integrins bind the sequence RGD in their respective ligands
(1). Of those integrins identified thus far,
4-,
5-,
8-,
IIb-, and
v-chains form heterodimers that mediate
RGD-dependent interactions. The ligands containing RGD are
generally found in the interstitial type of extracellular matrix. Major
non-RGD-dependent ligands include various collagen and
laminin isoforms. Although both collagens and laminins contain the RGD
sequence in their primary sequences, these RGD sequences are cryptic
(6-9) and are not normally accessible to cells in the native proteins,
but they may be exposed during growth and reorganization events of the
extracellular matrix.
Another subdivision of integrins can be made based on structural
similarities of the
-chains. A number of integrins contain an
extracellular (10, 11) that is homologous to collagen binding present
in von Willebrand factor (12). The I domain constitutes an inserted
domain of approximately 200 amino acids that is present in eight known
integrins (
1,
2,
10,
L,
M,
X,
D,
and
E) (5, 10). Structural analysis of integrin I
domains crystallized in the presence of Mg2+ have revealed
the presence of a characteristic metal ion-dependent adhesion site motif shown to be critical for ligand binding (13). Integrin
-chains containing the I domain are not cleaved into heavy
and light chains, although the rat
1 chain possesses a proteolytic cleavage site near the membrane-spanning region (14, 15).
For I domain integrins, the principal ligand binding sites are found
within the I domain (10). Known ligands for I domains found within the
1 integrin subfamily include laminins and collagens (
1
1 and
2
1
integrins) (16-19), and Echovirus (
2
1
integrin) (20).
Structure comparisons have suggested that integrins fold into a
so-called seven-bladed
-propeller structure that forms one globular
domain with the ligand binding region on the upper surface (21). The I
domain is inserted between blades 2 and 3 in this propeller, and
divalent cation binding sites are located on the lower surface in
blades 4-7 (22, 23). Studies of
2 integrins have
revealed that proper folding of the
2-chain is dependent on the presence of the
L-chain, but that the I domain
folds independently of other structural elements in the
- and
-chains (24). In integrin
-chains, a less conserved stalk region
separates the predicted
-propeller from the short transmembrane
region. This stalk region may possibly be involved in transducing
conformational changes between the extracellular and intracellular
regions, as well as mediating protein-protein interactions. Although
integrins take part in cell signaling events, the cytoplasmic tail is
short and lacks enzymatic activity. The sequence GFFKR is conserved in
a majority of integrin
-subunit cytoplasmic tails and has been shown
to be important for calreticulin binding (25).
Cellular interactions with the extracellular matrix during muscle
formation and in muscular dystrophy have received increased interest
during the past years. In the early 1960s, a mutant was described in
Drosophila that was characterized by the detachment of
muscles from their attachment points at the time of the first embryonic
muscle contraction, causing the embryos to assume a spheroid shape
(26). The mapping of the molecular defect in the lethal myospheroid
mutant in 1988 to an integrin
-chain (27) was the first evidence for
a role of integrins in maintaining muscle integrity. More recently,
refined analysis of Drosophila mutants has indicated
distinct roles for integrins in muscle end point attachments and
sarcomere structure (28). The Drosophila integrins are all
cleaved
-chains and share many features with vertebrate integrins
such as the ability to cluster into focal contacts (29).
The finding that inactivation of the
7 integrin gene in
the mouse (30) and mutations in the human ITGA7 gene (31)
both cause muscular dystrophy, affecting mainly muscle attachment
points, indicates a striking conservation of integrin function during evolution. Of the 11 members of the
1 subfamily,
7 exists as a major integrin
-chain (32, 33)
associated with the
1D integrin chain in the adult
skeletal muscle sarcolemma (34). Intriguingly, mutations in the
basement membrane protein laminin
2-chain (35-37) cause
a more severe disease than that observed for the laminin receptor
integrin
7
1 (30). This indicates that
other receptors for laminins exist in muscle.
We recently identified a novel integrin on cultured human fetal muscle
cells (38). In the current study, we describe the cloning and
characterization of this novel I domain-containing,
1-associated integrin chain, which is expressed in
muscle tissues.
 |
EXPERIMENTAL PROCEDURES |
Cell Cultures--
The human fetal myoblast/myotube cultures
were derived from clone G6 originating from a thigh muscle of a
73-day-old aborted fetus (Ref. 39; referred to as G6 hereafter).
Cultures of G6 and 2.5-year postnatal human satellite XXVI cells, a
gift from Dr. Helen Blau (Stanford University, Stanford, CA), were
grown as reported previously (39). Human rhabdomyosarcoma cell lines RD
(ATCC CCL-136) and A204 (ATCC CRL-7900) were grown in Dulbecco's modified Eagle's medium (Swedish Agricultural University, Uppsala, Sweden) supplemented with 10% fetal calf serum.
RNA Isolation and cDNA Synthesis--
Total RNA from G6 and
XXVI myoblasts and (the same cells differentiated for 3 or 7 days) and
RD and A204 cell lines was isolated using the RNeasy Midi kit (Qiagen)
according to the manufacturer's instructions. Poly(A) RNA was
extracted from the total RNA of G6 and XXVI cells using the Dynabeads
mRNA Direct kit (DYNAL A.S., Oslo, Norway).
PCR1-based Cloning and
Generation of Human
11 Probes--
First-strand
cDNA was generated from 1 µg of G6 mRNA using a reverse
transcription-PCR kit (Perkin-Elmer). Advantage cDNA Polymerase Mix
(CLONTECH) was used in PCR amplifications
using two different pairs of primers: 1) 5'-ACGGGAGACGTGTACAAGTG-3' (forward) and 5'-AAAGTGCTGAACCTCCACCC-3' (reverse), and 2)
5'-CACCATCCACCAGGCTATGC-3' (forward) and 5'-TTAGCGTTCCGTTATAAACA-3'
(reverse). The PCR conditions were 25 cycles of 94 °C for 4 min (hot
start), 94 °C for 30 s, 55 °C for 30 s, and 72 °C
for 1 min. Two products, named PCR1 and PCR2, were obtained (Fig. 1),
subcloned into the plasmid vector TA (Invitrogen), and sequenced. A
single product of 1.4 kb in size, named PCR3 (Fig. 1), was amplified
using primers 1 (forward) and 2 (reverse) and human heart
Marathon-Ready cDNA (CLONTECH) as a template.
Annealing temperatures in the applied touch-down program were as
follows: 68 °C, 1 min, 5 cycles; 65 °C, 1 min, 5 cycles; and
60 °C, 1 min, 25 cycles. Other steps were as described above. After
the final cycle, the reactions were extended for an additional 7 min at
72 °C, followed by a hold step at 4 °C. To obtain the sequence
covering the 5' end, rapid amplification of cDNA ends (RACE) was
performed according to the manufacturer's instructions (Marathon
cDNA Amplification kit; CLONTECH) using cDNA prepared from G6 mRNA and the gene-specific antisense
primer 5'-CTTGGAGAACCTGAAGTTGGAGTTGAC-3'. Amplification was
carried out applying the touch-down program (see above). To identify
relevant products, 10 µl of each RACE product were resolved on a 1%
agarose gel and subjected to Southern blot analysis as described
previously (40). PCR2 (see above) was labeled with
[
-32P]dCTP (Amersham Pharmacia Biotech) using the
RedyprimeII DNA labeling system (Amersham Pharmacia Biotech) and used
as a hybridization probe. One specific signal was detected.
Corresponding cDNA was purified (Gel Extraction kit; Qiagen),
cloned into the TA vector, and sequenced (see Fig. 1).
Screening of cDNA Libraries--
A
ZAP custom-made G6
cDNA library (Stratagene) was screened with PCR2 (see above) as a
probe. The screening procedure (carried out as described in Ref. 40)
resulted in two clones representing the 5' noncoding region and the
beginning of the coding part of integrin
11 (Fig. 1). To
obtain additional sequence, a human uterus 5'-stretch
gt11 cDNA
library (CLONTECH) was screened with a mixture of
PCR1 and PCR2 as probes. The probes were labeled with
[
-32P]dCTP using Ready-To-Go DNA labeling beads
(Amersham Pharmacia Biotech). Three clones (Fig. 1,
1.1-1.3) representing parts of
11 cDNA
were obtained. Rescreening of the human uterus 5'-stretch
gt11
cDNA library with probe
290 (corresponding to nucleotides 2183-2473 in Fig. 1) yielded three more clones (Fig. 1,
2.1-2.3) covering the rest of
11 cDNA.
Positive clones were plaque-purified, and the phage DNA was isolated
using the Lambda Midi kit (Qiagen) and then subcloned into the
Bluescript SK or pUC19 plasmid vectors before sequencing.
Northern Hybridization--
A filter containing 6 µg of the
poly(A) RNA from G6 and XXVI cells and 10 µg of the total RNA from RD
and A204 cells and a Human Multiple Tissue Northern blot containing
poly(A) RNA from adult human tissues (CLONTECH)
were hybridized at 68 °C in ExpressHyb solution
(CLONTECH) with probes labeled as described above.
The probes used were PCR1, PCR2, cDNA clone 1.3 (Fig. 1), 3RA (a
1.8-kb cDNA specific for human integrin
1 mRNA,
a generous gift from E. E. Marcantonio (Columbia University, New
York, NY)), a 1.1-kb cDNA clone recognizing human
glyceraldchyde-3-phosphate dehydrogenase mRNA, and a 1.8-kb
cDNA clone recognizing human
-actin (both from
CLONTECH).
cDNA Sequencing and Sequence Analysis--
All PCR fragments
and cDNA clones were sequenced on both strands either manually (29)
or using an ABI 310 Genetic Analyzer automatic sequencer. Sequences
were analyzed with the aid of the MacVectorTM 6.0, DNA Star,
FakturaTMNEW 1.2.0, and Sequence Navigator 1.0.1 software programs. A
distance tree of all I domain-containing integrin
subunits was
assembled using SEAVIEW and PHYLO_WIN software (41). The percentage
similarity between every two members in the I domain integrin subfamily
was calculated by the formula I = (1
D) × 100, where I is identity, and
D is distance.
Antibodies--
A polyclonal antiserum (
11 cyt)
was produced against the peptide CRREPGLDPTPKVLE from the integrin
11 cytoplasmic domain. Peptide synthesis and conjugation
to keyhole limpet hemocyanin, immunization of rabbits, and affinity
purification were performed at Innovagen AB (Lund, Sweden). The
monoclonal antibody MAB 13 against integrin
1 was
obtained from S. K. Akiyama (National Institute of Environmental
Health Sciences, National Institutes of Health). Monoclonal antibodies
to integrin
1 (clone FB12, sold as MAB 1973) and
integrin
2 (clone BHA2.1, sold as MAB 1998) were both
obtained from Chemicon (Temecula, CA). The monoclonal antibody to
vinculin (clone hVIN-1) was from Sigma. Secondary fluorescence
antibodies (CY3TM-coupled goat-anti-rabbit IgG and
FITC-coupled goat anti-mouse IgG of multiple labeling grade) were from
Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).
Immunoprecipitation and SDS-PAGE--
G6 and XXVI cells were
labeled with [35S]cysteine/methionine and subjected to
immunoprecipitation and SDS-PAGE as reported previously (38). The
two-step procedure used to dissociate integrin heterodimers was carried
out as follows. After incubation of samples with
1 antibody and capture with GammaBind G-Sepharose (Amersham Pharmacia Biotech), 100 µl of 1% SDS were added to the washed beads that were
then boiled for 5 min. 10 mM Tris-HCl, pH 7.4, 0.15 M NaCl, and 1% Triton X-100 were added to a final volume
of 1 ml, and the lysate was incubated with GammaBind G-Sepharose for
1 h. The incubation with GammaBind G was performed to ensure that
no reactive
1 antibodies remained. After the removal of
GammaBind G-Sepharose,
11 integrin antibody was added
for an additional 2 h, followed by capture with protein
A-Sepharose (Amersham Pharmacia Biotech) and boiling in SDS-PAGE sample buffer.
Chromosomal Localization--
Chromosomal localization of the
human integrin
11 was performed by using a combination
of the fluorescence in situ hybridization (FISH) technique
and 4',6-diamidino-2-phenylindole banding essentially as described
previously (42). The 1.4-kb reverse transcription-PCR product PCR3 was
used as a hybridization probe.
Surface Iodination and Affinity Chromatography--
Cultured
XXVI cells were surface-iodinated as described previously (38). Labeled
cells were solubilized in 1 ml of solubilization buffer (10 mM Tris-HCl, pH 7.4, 15 mM NaCl, 1% Triton
X-100, 1 mM MgCl2, 1 mM
CaCl2, and 1 mM MnCl2) and
centrifuged at 14,000 × g for 20 min, and soluble
membrane proteins were applied to a collagen type I-Sepharose (bovine
collagen type I from Vitrogen (Collagen Corp., Palo Alto, CA) coupled
to CNBr-activated Sepharose CL-4B at 3 mg/ml gel as described
previously (14)), equilibrated in solubilization buffer. After a 1-h
incubation, the column was washed extensively with buffer A (10 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM MnCl2, and 0.1% Triton X-100) and with 10 column volumes of buffer A without NaCl. Bound proteins were eluted
with 20 mM EDTA, 10 mM Tris-HCl, pH 7.4, and
0.1% Triton X-100. Peak fractions were pooled and concentrated by
immunoprecipitation with
1 integrin and
11 integrin antibodies as described under
"Immunoprecipitation and SDS-PAGE." Eluted fractions and captured
proteins were analyzed on 7.5% SDS-PAGE gels, followed by autoradiography.
Indirect Immunofluorescence--
Cells cultured on coverslips
were washed in serum-free medium and fixed for 8 min in acetone at
20 °C. Nonspecific binding sites were blocked by incubating with
10% goat serum diluted in phosphate-buffered saline. In the double
immunofluorescene staining protocol, primary antibodies
(anti-
11 cyt (rabbit antibody) and anti-vinculin (mouse
antibody)) were simultaneously incubated with fixed cells for 1.5 h at +37 °C. Specifically bound antibodies were detected using
anti-rabbit Cy3 IgG and anti-mouse FITC IgG. Stained cells were mounted
in VectashieldTM mounting medium (Vector Laboratories Inc., Burlingame,
CA) and visualized and photographed under a Zeiss light microscope
equipped with optics for observing fluorescence.
 |
RESULTS AND DISCUSSION |
cDNA Cloning of a Novel Integrin
Chain--
A number of
approaches were used to determine the nature of the integrin chain that
we had previously characterized on human fetal G6 muscle cells and
named
mt (38). Applying PCR with mRNA from fetal muscle cells as
a template together with degenerate primers to conserved regions of
integrin
-subunits (43), we amplified cDNA for
1,
4,
5,
6, and
v integrin chains (data not shown), but we failed to
amplify the novel integrin. However, while searching through the
literature, we came across two integrin sequences obtained in a
subtractive hybridization protocol comparing human primary myoblasts
with the rhabdomyosarcoma cell line RD (44). After having confirmed
that these sequences could be amplified by PCR from human fetal G6
myoblast cDNA, PCR was performed assuming that these sequences were
derived from the same transcript. In this manner, a 1.4-kb cDNA
fragment with an integrin-like sequence was obtained. Screening of a
human fetal myoblast cDNA library and 5' RACE yielded an additional
5' sequence. We determined the mRNA expression pattern in a number
of human tissues (see below) and observed a high mRNA expression in
the uterus. Screening of a uterus cDNA library resulted in the
identification of the complete open reading frame. A schematic
illustration of the cloning strategy is shown in Fig.
1.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic organization of PCR fragments and
cDNA clones representing different parts of the full-length
sequence of the integrin 11
subunit. A, clones 1.1-1.3 and 2.1-2.3 are from the
first and the second round of screening, respectively. Fragment 0.0 represents a 5' RACE product as well as a clone obtained from screening
of the G6 library. PCR fragments 1-3 and a SacI fragment of
clone 1.3, 290, are marked with thick lines. Names and
positions of all of the clones on the scheme are shown in tabulated
form in B. B, names of the PCR-amplified
fragments and cDNA clones shown in A are in the
left column, and their positions in the full-length cDNA
of integrin 11 are shown in the right column.
|
|
cDNA Sequence and Predicted Amino Acid Sequence of
11 Integrin Chain--
By sequence analysis of cDNA
clones and 5' RACE products, we obtained a continuous sequence of 3983 nucleotides composed of a 90-nucleotide 5' noncoding sequence, a
3564-nucleotide open reading frame, and a 329-nucleotide 3' noncoding
sequence. Translation of the sequence predicts an integrin
-chain-like precursor of 1188 amino acids including a 22-amino
acid-long signal peptide (Fig. 2; GenBank
accession number AF137378). The mature 1166-amino acid-long peptide is
larger than any other currently identified integrin
-chain (with the
closest being
E, which is composed of 1160 amino acids
(45)). The 1115-amino acid-long predicted extracellular domain contains
seven FG-GAP repeats in the amino-terminal end with an inserted I
domain between repeats 2 and 3. The I domain consists of 195 amino
acids and includes a conserved metal ion-dependent adhesion
site motif. In addition to the metal chelating site in the I domain,
three additional potential divalent cation binding motifs with the
consensus sequence DXD/NXDXXXD are
present in repeats 5-7. A total of 20 cysteines are located in the
extracellular domain. Of these, 16 are conserved in the most closely
related integrin
10- and
1-chains, and
they may contribute to intramolecular disulfide bonds. Nonconserved
cysteines were found at positions Cys606,
Cys806, Cys817, and Cys988. Mapping
of cysteines in the suggested
-propeller structure shows that the
first three disulfide bonds are likely to stabilize blades 1 and 2 of
the
-propeller, whereas the remaining bonds are found outside the
propeller region, in the stalk region toward the transmembrane domain.
16 potential N-glycosylation sites are present in
11. The transmembrane region (amino acids 1142-1164) is
23 amino acids long and is followed by a cytoplasmic tail of 24 amino
acids. The cytoplasmic tail contains the sequence GFFRS instead of the
conserved GFFKR sequence found in all other
-chains except
8-
10. It will be interesting to
determine the importance of this sequence in defining the cytoplasmic
domain as well as its possible ability to bind calreticulin and other
intracellular components.

View larger version (89K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleotide and deduced amino acid sequence of
the human integrin 11 chain.
The putative signal peptide is underlined in
bold, the I domain is boxed, potential
N-linked glycosylation sites are marked with
asterisks, cysteines are underlined, potential
divalent cation binding motifs are double underlined, and
the transmembrane domain is underlined with
dashes. A 22-amino acid insert is boxed in
bold.
|
|
Comparison of Integrin
11-Chain with Other Integrin
-Chains--
Alignment of the predicted
11 integrin
amino acid sequence with other integrin sequences shows the highest
overall identity with
10 (42% identity),
1 (37% identity), and
2 (35% identity), followed by the remaining I domain-containing integrin subunits. Of the
non-I domain-containing integrins,
4 and
9 are the most similar to
11. A distance
tree shows that
10 and
11 form a separate
branch from the most closely related
1 and
2 integrin chains (Fig.
3). The similarity with other integrins
is particularly high in the amino-terminal
-propeller part but is
lower in the stalk region. Comparison of
1 integrin with
2 integrin has pointed to the presence of a 38-residue
insert in the
-propeller region of the
1 integrin
chain (15). Like the
1 chain,
11 also
contains inserted amino acids not present in the other I
domain-containing integrin chains. However, in the
11
chain, these are found within the stalk region at amino acids 804-826.
The exact border of the predicted insertion varies depending on the
alignment method and the parameters chosen, but it is predicted to span
at least 22 amino acids. The insert contains two cysteines and shows no
significant similarity to other integrin sequences (see Fig. 2). We do
not believe that the predicted inserted sequence represents a cloning artifact because it is present in three independently analyzed clones.
Other examples of non-I domain inserted sequences are found in the
Drosophila
PS2 chain, in which developmentally regulated splicing in the ligand binding region modulates ligand affinity (46).
In the
7 integrin chain, splicing in the extracellular domain between predicted blades 2 and 3 in the
-propeller generates the X1 and X2 variants, affecting the binding to laminin-1 in a
cell-specific manner (47). In the more closely related
1 integrin chain, the 38 extra amino acids are present in a position that
is predicted to be in the beginning of the sixth blade of the
seven-bladed propeller. Thus far, there is no evidence that the extra
amino acids in either
1 or
11 arise by
alternative splicing. In
11, the predicted inserted
region is outside the
-propeller and most likely does not directly
affect ligand binding. It is nevertheless interesting to note that by
binding to the stalk region of certain integrin
-chains, tetraspan
proteins can recruit phosphatidylinositol 4-kinase and protein kinase C to integrin complexes (48). Likewise the extracellular
membrane-proximal parts of certain integrin
-chains have been shown
to be involved in Shc-mediated integrin signaling (49).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 3.
A distance tree of the I
domain-containing -integrin subfamily
members. A tree was assembled using ClustalW multiple
alignment, based on the SEAVIEW and PHYLOWIN software. A
scale at the bottom shows the percentage
identity.
|
|
Analysis of the sequences identified during screening for genes
up-regulated during tadpole regression revealed a partial sequence,
which at the time was reported to show the highest similarity to
integrin
1 (41% identity) (50). This sequence, when
translated (amino acids 1-116), shows 71% identity to human
11 and thus most likely represents the
Xenopus orthologue of
11 rather than that of
the
1. These data suggest that
11 is well
conserved during evolution.
Chromosomal Localization of the Integrin
11
Gene--
A fluorescent cDNA probe was used for in situ
hybridization on metaphase chromosome spreads. The analysis shows that
the integrin
11 gene (ITGA11) is located on
chromosome 15q23 (Fig. 4). The genes for
I domain-containing integrins
1 and
2 are
both present on chromosome 5 (51, 52), just as the genes for the
closely related
2 integrin-associated
-chains all map
to chromosome 16 (53). Interestingly, the
11 gene and
the closely related
1 and
2 genes map to
different chromosomes. It will be of evolutionary interest to determine
the chromosomal localization of the integrin
10 gene.
Curiously, a form of Bardet-Biedl syndrome characterized by retinitis
pigmentosa, polydactyly, obesity, hypogenitalism, mental retardation,
and renal anomalies maps to 15q22-23 (54).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 4.
Chromosome mapping of the ITGA11 gene by FISH. A, the left panel shows the
FISH signals on human chromosome 15; the right panel shows
the same mitotic figure stained with 4',6-diamino-2-phenylindole to
identify human chromosome 15. B, diagram of the FISH mapping
result for probe PCR3 based on a detailed analysis of 10 different
images. Each dot represents the double FISH signals detected
on human chromosome 15.
|
|
Expression Pattern of
11 mRNA in Adult
Tissues--
Northern blot analysis of mRNA from various adult
human tissues shows the highest level of expression of
11 in the adult human uterus. A strong signal is also
noted in the heart, whereas intermediate levels of
11
mRNA are present in skeletal muscle, and intermediate to low levels
are present in other adult nonmuscle tissues such as the pancreas,
kidney, and placenta (Fig. 5; data not
shown). For a comparison, the same blot was probed for the closely
related
1 integrin mRNA (Fig. 5). A striking
difference in the expression levels of
1 and
11 was observed in the smooth muscle-rich uterus, which
appears to lack
1. Immunohistochemical analysis and
in situ hybridizations will elucidate the detailed distribution of
11 protein and mRNA in muscle and
other tissues. Neither
1 (33) nor
2 (55)
is present in muscle fibers, and the distribution of
10 in skeletal muscle tissues is not known (5). Hence,
no I domain-containing integrin has yet been reported to be expressed
in the skeletal muscle sarcolemma. Recently, the gene for
1 integrin was inactivated in mice, resulting in mice with an apparently normal phenotype (56). More careful analysis revealed a phenotype characterized by a hypocellular skin (57) and aberrant regulation of collagen synthesis (58). It will be
interesting to compare sites of overlapping expression among
1,
2, and
10 integrins and
to use reagents to
10 and
11 to examine
possible functional compensatory mechanisms in
1
integrin-deficient mice.

View larger version (108K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of integrin 11 and 1 subunit mRNAs in adult human
tissues. Integrin 11 mRNA and integrin
1 mRNA were analyzed on a membrane with RNA from
various adult human tissues where mRNA loading was normalized with
respect to -actin. Probes used for hybridizations are marked on the
left. The size standard is marked to the right.
Note that the -actin probe reacts with 2 kb of -/ -actin
transcripts and the muscle-specific 1.8-kb -actin message.
|
|
Biochemical Characterization of
11
Protein--
After the cloning of the full-length
11
integrin cDNA, it was essential to determine whether the predicted
amino acid sequence was identical to the novel uncleaved
1 integrin-associated
-chain that we had previously
noted to be up-regulated during in vitro differentiation of
human myoblasts (38). To answer this question, we raised antibodies to
the cytoplasmic tail of the integrin
11 chain.
Immunoprecipitation from the human satellite cells showed that the
antibodies precipitated a 145-kDa
11 band associated with a 115-kDa
1 band (Fig.
6A) in SDS-PAGE under
nonreducing conditions. Under reducing conditions, the
11 band migrated as 155 kDa (see Fig. 6B).
From the translated amino acid sequence, a Mr of
133,400 is predicted for the
11 chain. Taking the 16 potential glycosylation sites into account, this fits well with the
observed 155-kDa band in SDS-PAGE. Under nonreducing conditions, the
145-kDa band is distinctly larger than
2 (Fig.
6A) and
10 integrin chains that co-migrate as
140-kDa bands, and
11 migrates well below the 180-kDa
integrin
1 band. The
2 (59) and
10 (5) integrin chains both contain 10 potential
glycosylation sites, whereas
1 contains 26 glycosylation
sites (60). The intermediate size of
11 in SDS-PAGE
compared with
1 and
2/
10 is thus most likely a result of differential glycosylation.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 6.
Biochemical characterization of integrin 11 chain and up-regulation of
corresponding protein and mRNA in myogenic cells.
A, 11 associates with the 1
integrin chain. Human XXVI muscle cells grown in differentiation medium
were metabolically labeled with [35S]cysteine/methionine,
and integrins were immunoprecipitated with the indicated antibodies
( 1, 2, and 11). Evidence
for the association of integrin 11 with the
1-subunit was obtained by treating proteins precipitated
with anti- 1 antibodies with SDS, followed by a second
precipitation with 11 antibodies (anti- 11
+ SDS). Precipitated proteins were resolved
on 7.5% SDS-PAGE gels in the absence of reducing agents, followed by
fluorography. B, induction of integrin 11
upon myogenic differentiation in vitro. G6 muscle cells were
metabolically labeled with [35S]cysteine/methionine when
growing in proliferation medium (mb, proliferating
myoblasts) and after 7 days in differentiation medium (mt,
myotubes). Integrins were precipitated with antibodies to
1 and 11, and the precipitates were
resolved on 7.5% SDS-PAGE gels both under nonreducing
(UNREDUCED) and reducing (REDUCED) conditions.
Lanes 1, 3, 5, and 7 are immunoprecipitations
with the antibody to integrin 1, and lanes 2, 4, 6, and 8 are immunoprecipitations with the antibody to
integrin 11. C, up-regulation of integrin
11 mRNA in differentiated myogenic cells. mRNA
was extracted from G6 and XXVI cells growing under proliferating
(p) or differentiating (d) conditions for 3 days
(d3) or 7 days (d7). Total RNA was isolated from
RD and A204 cells. Following separation of RNA on agarose gel and
transfer to the membrane, the filter was hybridized with probes to
11 integrin ( 11) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The size of bands in RNA standard (in kb) is marked
to the right.
|
|
To show that
11 is associated with the
1-subunit, we performed a two-step immunoprecipitation
procedure. Integrins were first precipitated with a monoclonal
anti-
1 integrin antibody, and GammaBind G-captured
integrins were then dissociated by boiling in 1% SDS. In the second
step, SDS was diluted tenfold, and antibodies to
11 were
added. As shown in Fig. 6A, antibodies to
11
immunoprecipitate only the 145-kDa band from the dissociated
precipitate initially captured with
1 antibodies.
Induction of
11 mRNA and Protein during Myogenic
Differentiation in Vitro--
We have previously determined that
mt is the major integrin
-chain that is up-regulated
during myogenic differentiation on human fetal myoblasts in
vitro (38). To compare
11 levels in myoblasts and
myotubes, immunoprecipitates were analyzed from myoblast cultures in
proliferation medium and from parallel cultures allowed to
differentiate and form myotubes in differentiation medium for 7 days.
Immunoprecipitation with both
1 and
11
antibodies showed that
11, like
mt, is
strongly up-regulated at the protein level in differentiating cultures
of human fetal muscle cells and satellite cells (Fig. 6B).
To determine whether the up-regulation occurs at the mRNA level or
the protein level, we analyzed
11 mRNA from
different differentiation stages (day 1, day 3, and day 7) (Fig.
6C). At day 3 in differentiation medium, a strong up-regulation of
11 mRNA was already noted,
establishing that the up-regulation of
11 integrin
protein occurs as a result of increased transcription or mRNA
stability. Based on similar SDS-PAGE migration patterns, similar
behavior under reducing conditions, association with the
1 integrin chain, and up-regulation during in
vitro differentiation of human fetal myoblasts, our data show that
11 integrin is identical with
mt.
Analysis of mRNA from the two rhabdomyosarcoma cell lines, RD and
A204 (Fig. 6C), did not provide evidence for the presence of
11 in either cell line. Based on the observed
up-regulation of
11
1 in human fetal
muscle cells and the presence of
11 message in adult
muscle, we suggest that the
11 integrin might be
involved in the early steps of muscle formation and that it may fulfill a stabilizing role in adult muscle tissues. The
7
integrin subunit is a major
1-associated integrin chain
in muscle, but genetic deletion of
7 leads to a fairly
mild muscular dystrophy (30). It remains to be seen whether
11 and
7 integrin chains have overlapping
functions in muscle.
Ligand Binding Specificity of
11
1
Integrin--
The I domain-containing integrins of the
1 integrin subfamily that have been identified thus far
all bind collagens (5, 15, 59). For
1 and
2 this binding capacity has been shown to reside within
the I domain (17, 18). To determine whether
11
1 also binds collagen, we performed
collagen type I-Sepharose chromatography of membrane proteins from
surface-iodinated XXVI satellite cells. Direct analysis of the EDTA
eluate revealed weak bands corresponding to the positions of
1,
2,
11, and
1 in parallel immunoprecipitations (Fig.
7a). The EDTA eluate was
concentrated by immunoprecipitation with
1 and
11 antibodies. As shown in Fig. 7, a prominent
11 band is present in the collagen I-Sepharose eluate.
The relatively weak
1 band in the proteins captured with
11 antibodies indicates that the
11
1 heterodimer partly dissociates in the
presence of EDTA.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 7.
Ligand binding properties of 11 1
integrin. a), collagen binding integrins on XXVI cells.
XXVI cells were surface-iodinated, and integrins were analyzed by
immunoprecipitation and collagen I-Sepharose affinity chromatography.
Immunoprecipitation reveals the presence of 1 integrins
(lane 1) 1 1 (lane
2), 11 1 (lane 3), and
2 1 (lane 4) at the surface of
XXVI cells. EDTA-eluted proteins bound to collagen I-Sepharose contain
weak bands in the position of 1, 11,
2, and 1 integrin chains (lane
5). Immunoprecipitations with 1 integrin antibodies
(lane 6) and 11 integrin antibodies
(lane 7) confirm the presence of 11 and
1 in the EDTA eluate. b),
11 1 localizes to focal contacts on
collagen. Indirect immunofluorescent visualization of vinculin
(A and B) and 11 integrin chain
(C and D) in human XXVI satellite cells seeded on
collagen type I (A and C) and fibronectin
(B and D). Note the localization of integrin
11 chain to focal contacts of cells allowed to attach to
collagen, and its complete absence on cells seeded on fibronectin.
Vinculin is found in focal contacts on both substrates. A
and C show the same cell double-stained for both antigens.
Scale bar, 20 µm.
|
|
To visualize the interaction of
11
1
integrin with collagen I in intact cells, myogenic cells expressing
11
1 were trypsinized and plated on
collagen and fibronectin for 1 h. The ability to form focal
contacts was investigated by double immunofluorescence staining for
11-chain and vinculin. As seen in Fig. 7b,
11 localizes to vinculin-positive focal contacts on
collagen, but not on fibronectin. Binding studies with
11 I domain expressed as a bacterial glutathione S-transferase-fusion protein also confirmed a specific
affinity for collagen I (2). Stable
transfections of
11 cDNA into cells with various
integrin backgrounds will allow a more detailed study of
11
1 interactions with different collagen
isoforms and possibly also with laminin isoforms. Combined with
in vivo distribution studies of
11
1, this is likely to yield valuable
information regarding the in vivo ligands for
11
1 in different tissues.
 |
ACKNOWLEDGEMENTS |
We are grateful to S. Akiyama for Mab 13 to
1 integrin, H. Blau for XXVI satellite cells, SeeDNA Biotech Inc.
for help with the chromosomal localization, Maido Remm for help with
the distance tree, and E. Marcantonio for integrin
1
cDNA. We acknowledge the technical assistance of P. Jalonen, G. Dombus, A. Wraith, and T. Timmusk and support from P. Ekblom.
 |
FOOTNOTES |
*
This work was supported by Medical Research Council Grants
12X-10817 (to D. G.) and 32X-13109 (to T. S.) and by grants from Gustaf V:s fond (to D. G.), Bergvalls stiftelse (to D. G.), and Ronald McDonald Barnfond (to T. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF137378.
To whom correspondence should be addressed. Tel.:
46-18-471-4175; Fax: 46-18-508095; E-mail:
Donald.Gullberg@zoofys.uu.se.
2
M. Höök, R. Rich, and R. Owens,
unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
PCR, polymerase
chain reaction;
kb, kilobases;
RACE, rapid amplification of cDNA
ends;
SDS-PAGE, SDS-polyacrylamide gel electrophoresis;
FISH, fluorescence in situ hybridization.
 |
REFERENCES |
| 1.
|
Hynes, R. O.
(1992)
Cell
69,
11-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Adams, J.,
and Watt, F. M.
(1993)
Development
117,
1183-1198[Medline]
[Order article via Infotrieve]
|
| 3.
|
Sastry, S. K.,
and Horwitz, A. F.
(1996)
Dev. Biol.
180,
455-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Gullberg, D.,
Tiger, C.-F.,
Lohikangas, L.,
and Velling, T.
(1998)
Front. Biosci.
3,
1028-1039
|
| 5.
|
Camper, L.,
Hellman, U.,
and Lundgren-Akerlund, E.
(1998)
J. Biol. Chem.
273,
20383-20389[Abstract/Free Full Text]
|
| 6.
|
Aumailley, M.,
Gerl, M.,
Sonnenberg, A.,
Deutzmann, R.,
and Timpl, R.
(1990)
FEBS Lett.
262,
82-86[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Pfaff, M.,
Aumailley, M.,
Specks, U.,
Knolle, J.,
Zerwes, H. G.,
and Timpl, R.
(1993)
Exp. Cell Res.
206,
167-176[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Davis, G. E.
(1992)
Biochem. Biophys. Res. Commun.
182,
1025-1031[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Goodman, S. L.,
Aumailley, M.,
and von der Mark, H.
(1991)
J. Cell Biol.
113,
931-941[Abstract/Free Full Text]
|
| 10.
|
Dickeson, S. K.,
and Santoro, S. A.
(1998)
Cell. Mol. Life Sci
54,
556-566
[CrossRef][Medline]
[Order article via Infotrieve] |
| 11.
|
Takada, Y.,
Kamata, T.,
Irie, A.,
Puzon-McLaughlin, W.,
and Zhang, X. P.
(1997)
Matrix Biol.
16,
143-151[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Colombatti, A.,
Bonaldo, P.,
and Doliana, R.
(1993)
Matrix
13,
297-306[Medline]
[Order article via Infotrieve]
|
| 13.
|
Lee, J.-O.,
Rieu, P.,
Arnaout, M. A.,
and Liddington, R. C.
(1995)
Cell
80,
631-635[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Gullberg, D.,
Turner, D. C.,
Borg, T. K.,
Terracio, L.,
and Rubin, K.
(1990)
Exp. Cell Res.
190,
254-264[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Ignatius, M. J.,
Large, T. H.,
Houde, M.,
Tawil, J. W.,
Barton, A.,
Esch, F.,
Carbonetto, S.,
and Reichardt, L. F.
(1990)
J. Cell Biol.
111,
709-720[Abstract/Free Full Text]
|
| 16.
|
Dickeson, S. K.,
Walsh, J. J.,
and Santoro, S. A.
(1997)
J. Biol. Chem.
272,
7661-7668[Abstract/Free Full Text]
|
| 17.
|
Calderwood, D. A.,
Tuckwell, D. S.,
Eble, J.,
Kühn, K.,
and Humphries, M. J.
(1997)
J. Biol. Chem.
272,
12311-12317[Abstract/Free Full Text]
|
| 18.
|
Tuckwell, D.,
Calderwood, D. A.,
Green, L. J.,
and Humphries, M. J.
(1995)
J. Cell Sci.
108,
1629-1637[Abstract]
|
| 19.
|
Tuckwell, D. S.,
Reid, K. B. M.,
Barnes, M. J.,
and Humphries, M. J.
(1996)
Eur. J. Biochem.
241,
732-739[Medline]
[Order article via Infotrieve]
|
| 20.
|
King, S. L.,
Kamata, T.,
Cunningham, J. A.,
Emsley, J.,
Liddington, R. C.,
Takada, Y.,
and Bergelson, J. M.
(1997)
J. Biol. Chem.
272,
28518-28522[Abstract/Free Full Text]
|
| 21.
|
Springer, T. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
65-72[Abstract/Free Full Text]
|
| 22.
|
Huang, C.,
and Springer, T. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3162-3167[Abstract/Free Full Text]
|
| 23.
|
Oxvig, C.,
and Springer, T. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4870-4875[Abstract/Free Full Text]
|
| 24.
|
Huang, C.,
Lu, C.,
and Springer, T. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3156-3161[Abstract/Free Full Text]
|
| 25.
|
Rojiani, M. V.,
Finlay, B. B.,
Gray, V.,
and Dedhar, S.
(1991)
Biochemistry
30,
9859-9866[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Wright, T. F.
(1960)
J. Exp. Zool.
143,
77-99[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
MacKrell, A. J.,
Blumberg, B.,
Haynes, S. R.,
and Fessler, J. H.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2633-2637[Abstract/Free Full Text]
|
| 28.
|
Bloor, J. A.,
and Brown, N. H.
(1998)
Genetics
148,
1127-1142[Abstract/Free Full Text]
|
| 29.
|
Gullberg, D.,
Fessler, L. I.,
and Fessler, J. H.
(1994)
Dev. Dyn.
199,
116-128[Medline]
[Order article via Infotrieve]
|
| 30.
|
Mayer, U.,
Saher, G.,
Fassler, R.,
Bornemann, A.,
Echtermeyer, F.,
von der Mark, H.,
Miosge, N.,
Poschl, E.,
and von der Mark, K.
(1997)
Nat. Genet.
17,
318-323[Medline]
[Order article via Infotrieve]
|
| 31.
|
Hayashi, Y. K.,
Chou, F.-L.,
Engvall, E.,
Ogawa, M.,
Matsuda, C.,
Hirabayashi, S.,
Yokochi, K.,
Ziober, B. L.,
Kramer, R. H.,
Kaufman, S. J.,
Ozawa, E.,
Goto, Y.,
Nonaka, I.,
Tsukahara, T.,
Wang, J.-Z.,
Hoffman, E. P.,
and Arahata, K.
(1998)
Nat. Genet.
19,
94-97[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Song, W. K.,
Wang, W.,
Foster, R. F.,
Bielser, D. A.,
and Kaufman, S. J.
(1992)
J. Cell Biol.
117,
643-657[Abstract/Free Full Text]
|
| 33.
|
Martin, P. T.,
Kaufman, S. J.,
Kramer, R. H.,
and Sanes, J. R.
(1996)
Dev. Biol.
174,
125-139[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Belkin, A.,
Zhidkova, N. I.,
Balzac, F.,
Altruda, F.,
Tomatis, D.,
Maier, A.,
Tarone, G.,
Koteliansky, V. E.,
and Burridge, K.
(1996)
J. Cell Biol.
132,
211-226[Abstract/Free Full Text]
|
| 35.
|
Miyagoe, Y.,
Hanaoka, K.,
Nonaka, I.,
Hayasaka, M.,
Nabeshima, Y.,
Arahata, K.,
Nabeshima, Y.,
and Takeda, S.
(1997)
FEBS Lett.
415,
33-39[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Xu, H.,
Christmas, P.,
Wu, X. R.,
Wewer, U. M.,
and Engv |